Killer genes in pancreatic cancer therapy

Cellular and Molecular Biology

Volumn 51, Issue 1, 2005, Pages 61-76

  Fogar, P ^a   Greco, E ^a   Basso, D ^a   Navaglia, F ^a   Plebani, M ^a   Pedrazzoli, S ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cytotoxic bacterial toxins; Killer genes; Pancreatic cancer; Viral and non viral delivery systems

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL TOXIN; CYTOKINE; CYTOSINE DEAMINASE; DNA POLYMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; K RAS PROTEIN; LIPOSOME; PROTEIN P53; SMAD4 PROTEIN; SOMATOSTATIN RECEPTOR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; CANCER THERAPY; CELL ENCAPSULATION; CYTOTOXICITY; DNA INTEGRATION; DNA VECTOR; ENDOCYTOSIS; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; METHYLATION; MUTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS CANCER; PARVOVIRUS; PHOSPHORYLATION; REVIEW; SUICIDE GENE; TUMOR GROWTH; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BACTERIAL TOXINS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; PANCREATIC NEOPLASMS;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); PARVOVIRUS;

EID: 29144508009     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S. and DePinho, R.A., Activated K-ras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17: 3112-3126.
2. Ammori, J.B., Colletti, L.M., Zalupski, M.M., Eckhauser, F.E., Greenson J.K., Dimick, J., Lawrence, T.S. and McGinn, C.J., Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J. Gastrointest. Surg. 2003, 7: 766-772.
3. Aoki, K., Yoshida, T., Matsumoto, N., Ide, H., Hosokawa, K., Sugimura, T. and Terada, M., Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum. Gene Ther. 1997, 8: 1105-1113.
4. Aoki, K., Yoshida, T., Matsumoto, N., Ide, H., Sugimura, T. and Terada, M., Suppresion of ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with ki-ras mutation but not those without ki-ras mutation. Mol. Carcinogen 1997, 20: 251-258.
5. Arteaga, C.L., Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Sem. Oncol. 2002, 29: 3-9.
6. Bardeesy, N. and DePinho, R.A., Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2002, 2: 897-909.
7. Barton, C.M. and Lemoine, N.R., Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer 1995, 71: 429-437.
8. Bauerschmitz, G.J., Barker, S.D. and Hemminki, A., Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. Int. J. Oncol 2002, 21: 1161-1174 (review).
9. Berinstein, N., Overview of therapeutic vaccination approaches for cancer. Sem. Oncol. 2003, 30: 1-8.
10. Berndt, C., Haubold, K., Wenger, F., Brux, B., Muller, J., Bendzko, P., Hillebrand, T., Kottgen, E. and Zanow, J., K-ras mutations in stools and tissue samples from patients with malignant and non-malignant pancreatic diseases. Clin. Chem. 1998, 44: 2103-2107.
11. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A. and McCormick, F., An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274(5286): 373-376.
12. Bishop, J.,S., Thull, N.M., Matar, M., Quezada, A., Munger, W.E., Batten, T.L., Muller, S. and Pericle, F., Antitumoral effect of a non-viral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil. Cancer Gene Ther. 2000, 7: 1165-1171.
13. Block, A., Chen, S.-H., Kosai, K.-I., Finegold, M. and Woo, S.L.C., Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997, 15: 25-34.
14. Bouvet, M., Bold, R.J., Lee, J., Evans, D.B., Abbruzzese, J.L., Chiao, P.J., McConkey D.J., Chandra, J., Chada, S., Fang, B. and Roth, J.A., Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann. Surg. Oncol. 1998, 5: 667-669.
15. Buscail, L., Saint-Laurent, N., Chastre, E., Vaillant, J.-C., Gespach, C., Capellà, G., Kalthoff, H., Lluis, F., Vaysse, N. and Susini, C., Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 1996, 56: 1823-1827.
16. Calbò, J., Marotta, M., Cascallo, M., Roig, J.M., Gelpi, J.L., Fueyo, J. and Mazo, A., Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther. 2001, 8: 740-750.
17. Carriò, M., Mazo, A., López-Iglesias, C., Estivill, X. and Fillat, C., Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells. Results in variable efficiency on the bystander killing: implications for gene therapy. Int. J. Cancer 2001, 94: 81-88.
18. Carriò, M., Romagosa, A., Mercadè, E., Mazo, A., Nadal, M., Gomez-Foix, A.-M. and Filial, C., Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of herpes simplex virus thymidine kinase gene. Gene Ther. 1999, 6: 547-553.
19. Cascallo, M., Mercade, E., Capella, G., Lluis, F., Fillat, C., Gomez-Foix, A.M. and Mazo, A., Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther. 1999, 6: 428-436.
20. Celinski, S.A., Fisher, W.E., Amaya, F., Wu, Y.Q., Yao, Q., Youker, K.A. and Li, M., Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografis. J. Surg. Res. 2003, 115: 41-47.
21. Chandler, L.A., Sosnowski, B.A., McDonald, J.R., Price, J.E., Aukerman, S.L., Baird, A., Pierce, G.F. and Houston, L.L., Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. Int. J. Cancer 1998, 78: 106-111.
22. Chen, W.B., Lenschow, W., Tiede, K., Fischer, J.W., Kalthoff, H., and Ungefroren, H. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J. Biol. Chem. 2002, 277: 36118-36128.
23. Collier, R.J. and Kandel, J., Structure and activity of diphteria toxin. I. Thiol dependent dissociation of a fraction of toxin into enzymatically active and inactive fragments. J. Biol. Chem. 1971, 246: 1496-1503.
24. Cook, T. and Urrutia, R., TIEG proteins join the Smads as TGF-β-regulated transcription factors that control pancreatic cell growth. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278: G513-G521.
25. Cowgill, S.M. and Muscarella, P., The genetics of pancreatic cancer. Am. J. Surg. 2003, 186: 279-286.
26. Delesque, N., Buscail, L., Esteve, J.-P., Saint-Laurent, N., Muller, C., Weckbecker, G., Bruns, C., Vaysse, N. and Susini, C., Sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 1997, 57: 956-962.
27. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nature Rev. 2004, 4: 11-22.
28. Duda, D.G., Sunamura, M., Lefter, L.P., Furukawa, T., Yokoyama, T., Yatsuoka, T., Abe, T., Inoue, H., Motoi, F., Egawa, S., Matsuno, S. and Horii, A., Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003, 22: 6857-6864.
29. El Kamar, F.G., Grossbard, M.L. and Kozuch, P.S., Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. The Oncologist 2003, 8: 18-34.
30. Elshami, A.A., Saavedra, A., Zhang, H., Kucharczuk, J.C., Spray, D.C., Fishman, G.I., Amin, K.M., Kaiser, L.R. and Albelda, S.M., Gap junction play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996, 3: 85-92.
31. Erbs, P., Regulier, E., Kintz, J., Leroy P., Poitevin, Y., Exinger, F., Jund, R. and Mehtali, M., In vivo cancer gene therapy by adenovirus-mediated transfer of bifunctional yeast cytosine deaminasi/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000, 60: 3813-3822.
32. Evoy D., Hirschowitz, E.A., Naama, H.A., Kui, X., Crystal, R.G., Daly J.M. and Lieberman, M.D., In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J. Surg. Res. 1997, 69: 226-231.
33. Faulds, D. and Rennie, C.H., Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 1990, 39: 567-638.
34. Fisher, W.E., Wu, Y.Q., Amaya, F. and Berger, D.H., Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J. Surg. Res. 2002, 105: 58-64.
35. Fogar, P., Greco, E., Basso, D., Habeler, W., Navaglia, F., Zambon, C.-F., Tormen, D., Gallo, N., Cecchetto, A., Plebani, M. and Pedrazzoli, S., Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur. J. Surg. Oncol. 2003, 29: 721-730.
36. Frankel, A.E., Beran, M., Hogge, D.E., Powell, B.L., Thorburn, A., Chen, Y.Q. and Vallera, D.A., Malignant progenitors from patients with CD87+ acute myelogenous leucemia are sensitive to a diphtheria toxin-urokinase fusion protein. Exp. Hematol. 2002, 30: 1316-1323.
37. Frankel, A.E., Neville, D.M., Bugge, T.A., Kreitman, R.J. and Leppla, S.H., Immunotoxin therapy of hematologic malignancies. Sem. Oncol. 2003, 30: 545-557.
38. Frankel, A.E., Powell, B.L. and Lilly, M.B., Diphtheria toxin coniugate therapy of cancer. In: Cancer Chemotherapy and Biological Response Modifiers, Annual 20, Giaccone, G, Schilsky R. and Sondel, P. (eds.), Elsevier Science, 2002, pp. 301-313.
39. Ghaneh, P., Greenhalf, W., Humphreys, M., Wilson, D., Zumstein, L., Lemoine, N.R. and Neoptolemos, J.P., Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 2001, 8: 199-208.
40. Giannini, C.D., Roth, W.K., Piiper, A. and Zeuzem, S., Enzymatic and antisense effects of a specific anti ki-ras ribozyme in vitro and in cell culture. Nucl. Acids Res. 1999, 13: 2737-2744.
41. Gilliam, A.D. and Watson, S.A., Emerginge biological therapies for pancreatic carcinoma. Eur. J. Surg. Oncol. 2002, 28: 370-378.
42. Greco, E., Fogar, P., Basso, D., Stefani, A.L., Navaglia, F., Zambon, C.-F., Mazza, S., Gallo, N., Piva, M.G., Scarpa, A., Pedrazzoli, S. and Plebani, M., Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas 2002, 25: 21-29.
43. Greenlee, R.T., Murray, T., Golden, S. and Wingo, P.A., Cancer statistics, 2000. Cancer J. Clin. 2000, 50: 7-33.
44. Guillermet, J., Saint-Laurent, N., Rochaix, P., Cuvillier, O., Levade, T., Schally A.V., Pradayrol, L., Buscail, L., Susini, C. and Bousquet, C., Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. PNAS 2003, 100: 155-160.
45. Hajri, A., Wack, S., Lehn, P., Vigneron, J.-P., Lehn, J.-M., Marescaux, J. and Aprahamian, M., Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes. Cancer Gene Ther. 2004, 11: 16-27.
46. Haller, D.G., New perspectives in the management of pancreas cancer. Sem. Oncol. 2003, 30(11): 3-10.
47. Harvey, B.-G., Hackett, N.R., El-Sawy, T., Rosengart, T.K., Hirschowitz, E.A., Lieberman, M.D., Lesser, M.L. and Crystal, R.G., Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 1999, 73: 6729-6742.
48. Hecht, J.R., Bedford, R., Abbruzzese, J.L., Lahoti; S., Reid, T.R., Soetikno, R.M., Kim, D.H. and Freeman, S.M., A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 2003, 9: 555-561.
49. Hotz, H.G., Gill, P.S., Masood, R., Hotz, B., Buhr, H.J,, Foitzik, T., Hines, O.J. and Reber, H.A., Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J. Gastrointest. Surg. 2002, 6: 159-166.
50. Howard, B.D., Boenicke, L., Schneider-Brachert, W. and Kalthoff, H., Enhanced retroviral transduction efficiency of pancreatic tumor cell lines using different envelope glycoproteins. Ann. N.Y. Acad. Sci. USA 1999, 880: 366-370.
51. Humphreys, M.J., Greenhalf, W., Neoptolemos, J.P. and Ghaneh, P., The potential for gene therapy in pancreatic cancer. Int. J. Pancreatol. 1999, 26: 5-21.
52. Hung, C.-F., Cheng, W.-F., Hsu, K.-F., Chai, C.-Y., He, L., Ling, M. and Wu, T.-C., Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 2001, 61: 3698-3703.
53. Hwang, R.F., Gordon, E.M., Anderson, W.F. and Parekh, D., Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998, 124: 143-150.
54. Ishii-Morita, H., Mechanism of 'bystander effect' killing in the herpes simplex thimidine kinase gene therapy model of cancer treatment. Gene Ther. 1997, 4: 244-251.
55. Jooss, K. and Chirmule, N., Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 2003, 10: 955-963.
56. Kanyama, H., Tomita, N., Yamano, T., Aihara, T., Miyoshi, Y., Ohue, M., Sekimoto, M., Salita, I., Tamaki, Y., Kaneda, Y., Senter, P.D. and Monden, M., Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res. 2001, 61: 14-18.
57. Katz, M.H. and Bouvet, M., Novel gene therapy approaches to pancreatic cancer. Int. J. Gastrointestinal Cancer 2003, 33: 89-97.
58. Keleg, S., Buchler, P., Ludwig, R., Buchler, M.W. and Friess, H., Invasion and metastasis in pancreatic cancer. Mol. Cancer 2003, 2: 14.
59. Kijima, H., Yamazaki, H., Nakamura, M., Scanlon, K.J., Osamura, R.Y. and Ueyama, Y., Ribozyme against mutant k-ras mRNA suppresses tumor growth of pancreatic cancer. Int. J. Oncol. 2004, 24: 559-564.
60. Kimura, M., Tagawa, M., Takenaga, K., Kondo, F., Yamaguchi, T., Saisho, H., Nakagawara, A. and Sakiyama, S., Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: a potentiality for cancer gene therapy. Cancer Let. 1998, 128: 47-53.
61. Kimura, M., Yoshida, Y., Narita, M., Takenaga, K., Takenouchi, T., Yamaguchi, T., Saisho, H., Sakiyama, S. and Tagawa, M., Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus. Int. J. Cancer 1999, 82: 549-555.
62. Kishida, T., Asada, H., Itokawa, Y., Cui, F.-D., Shin-Ya, M., Gojo, S., Yasutomi, K., Ueda, Y., Yamagishi, H., Imanishi, J. and Mazda, O., Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 2003, 8: 552-558.
63. Kita, K., Saito, S., Morioka, C.Y. and Watanabe, A., Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int. J. Cancer 1999, 80: 553-558.
64. Kobayashi, S., Shirasawa, H., Sashiyama, H., Kawahira, H., Kaneko, K., Asano, T. and Ochiai, T., pP16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin. Cancer Res. 1999, 5: 4182-4185.
65. Kreitman, R.J., Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 2003, 5: 44-51.
66. Kroger, J-C., Benz, S., Hoffmeyer, A., Bago, Z., Bergmeister, H., Gunzburg, W.H., Karle, P., Kloppel, G., Losert, U., Muller, P., Nizze, H., Obermaier, R., Probst, A., Renner, M., Saller, R., Salmons, B., Schwendenwein, I., von Rombs, K., Weissner, R., Wagner, T., Hauenstein, K. and Lohr, M., Intra arterial instillation of microencapsulated, ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting. Pancreatology 2003, 3: 55-63.
67. Kumar, N.M. and Gilula, N.B., The gap junction communication channel. Cell 1996, 84: 381-388.
68. Kuriyama, S., Kikukawa, M., Masui, K., Okuda, H., Nakatani, T., Sakamoto, T., Yoshiji, H., Fukui, H., Ikenaka, K., Mullen, C.A. and Tsujii, T., Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int. J. Cancer 1999, 81: 592-597.
69. Kuriyama, S., Minoro, A., Yamazaki, M., Tsujinoue, H., Nakatani, T., Akahane, T., Toyokawa, Y., Kojima, H., Okamoto, S. and Fukui, H., Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand. J. Gastroenterol. 1999, 34: 1033-1041.
70. Lemoine, N.R., Jain, S., Hughes, C.M., Staddon, S.L., Maillet, B., Hall, P.A. and Kloppel, G., Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992, 102: 230-236.
71. Li, J., Weghorst, C.M., Tsutsumi, M., Poi, M.J., Knobloch, T.J., Casto, B.C., Melvin, W.S., Tsai, M.D. and Muscarella, P., Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis 2004, 25: 263-268.
72. Li, Y., McCadden, J., Ferrer, F., Kniszewski, M., Carducci, M., Simons, J. and Rodriguez, R., Prostate-specific expression of the diphtheria toxin Achain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002, 62: 2576-2582.
73. Liu, F., Pouponnot, C. and Massaguè, J., Dual role of the Smad4/DPC4 tumor suppressor in TGF -inducible transcriptional complexes. Genes Dev. 1997, 11: 3157-3167.
74. Liu, S., Aaronson, H., Mitola, D.J., Leppla, S.H. and Bugge, T.H., Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. USA 2003, 100: 657-662.
75. Liu, S., Bugge, T.H. and Leppla, S.H., Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent antral toxin. J. Biol. Chem. 2001, 276: 17976-17984.
76. Liu, T.F., Cohen, K.A., Ramage, J.G., Willingham, M.C., Thorburn, A.M. and Frankel, A.E., A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res. 2003, 63: 1834-1837.
77. Lohr, M., Hoffmeyer, A., Kroger, J.-C., Freund, M., Hain, J., Holle, A., Karle, P., Knofel, W.T., Liebe, S., Muller, P., Nizze, H., Renner, M., Saller, R.M., Wagner, T., Hauenstein, K., Gunzburg, W.H. and Salmons, B., Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001, 357: 1591-1592.
78. Lohr, M., Muller, P., Karle, P., Stange, J., Mitzner, S., Jesnowski, R., Nizze, H., Nebe, B., Liebe, S., Salmons, B. and Gunzburg, W.H., Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 1998; 5: 1070-1078.
79. Longley D.B., Harkin, D.P. and Johnston, P.G., 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3: 330-338.
80. Luttges, J., Schlehe, B., Menke, M.A., Vogel, I., Henne-Bruns, D. and Kloppel, G., The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 1999, 85: 1703-1710.
81. Makinen, K., Loimas, S., Wahlfors, J., Alhava, E. and Janne, J., Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J. Gene Med. 2000, 2: 361-367.
82. Mendelsohn, J., The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Rel. Cancer 2001, 8: 3-9.
83. Mesnil, M. and Yamasaki, H., Bystander effects in herpes simplex virus-thimidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000, 60: 3989-3999.
84. Mishra, G., Liu, T.F. and Frankel, A.E., Recombinant toxin DAB(389)EGF is cytotoxic to human pancreatic cancer cells. Export. Opin. Biol. Ther. 2003, 3: 1173-1180.
85. Moore, P.S., Sipos, B., Orlandini, S., Sorio, C., Real, F.X., Lemoine, N.R., Gress, T., Bassi, C., Kloppel, G., Kalthoff, H., Ungefroren, H., Lohr, M. and Scarpa, A., Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virch. Arch. 2001, 439: 798-802.
86. Mortimer, I., Tam, P., MacLachlan, I., Graham, R.W., Saravolac, E.G. and Joshi, P.B., Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Ther. 1999, 6: 403-411.
87. Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C. and Kirn, D., Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovinis (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 2001, 8: 308-315.
88. Nakada, Y., Saito, S., Ohzawa, K., Morioka, C.Y., Kita, K., Minemura, M., Takahara, T. and Watanabe, A., Antisense oligonucleotides specific to mutated k-ras genes inhibit invasiveness of human pancreatic cancer cell lines. Pancreatology 2001, 1: 314-319.
89. Pearson, S.A., Koch, P.E., Atkinson, N., Xiong, M., Finberg, R.W., Roth, J.A. and Fang, B., Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin. Cancer Res. 1999, 5: 4208-4213.
90. Peng, B., Fleming, J.B., Breslin, T., Grau, A.M., Fojioka, S., Abbruzzese, J.L., Evans, D.B., Ayers, D., Wathen, K., Wu, T., Robertson, K.D. and Chiao, P.J., Suppression of tumorigenesis and induction of p 15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin. Cancer Res. 2002, 8: 3628-3638.
91. Peng, W., Vverbitsky, A., Bao, Y. and Sawicki, J.A., Regulated expression of diphtheria toxin in prostate cancer cells. Mol. Ther. 2002, 6: 527-545.
92. Qiao, J. and Caruso, M., PG13 packaging cells produce recombinant retroviruses carrying a diphtheria toxin mutant which kills cancer cells. J. Virol. 2002, 76: 7343-7348.
93. Reni, M., Passani, P., Panucci, M.G., Nicoletti, R., Ggalli, L., Balzano, G., Zerbi, A., Di Carlo, V. and Villa, E., Definitive results of phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. I2001, 19: 2679-2686.
94. Rigg, A.S. and Lemoine, N.R., Genetic prodrug activation therapy for pancreatic cancer. Ann. N.Y. Acad. Sci. USA 1999, 880: 319-325.
95. Ritter, C.A. and Arteaga, C.L., The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Sem. Oncol. 2003, 30: 3-11.
96. Rochaix, P., Delesque, N., Estève, J.-P., Saint-Laurent, N., Voigt, J.-J., Vaysse, N., Susini, C. and Buscail, L., Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther. 1999, 10: 995-1008.
97. Rodicker, F. and Putzer, B.M., pP73 is effective in p53-null pancreatic cancer cells resistant to wild-type XP53 gene replacement. Cancer Res. 2003, 63: 2737-2741.
98. Rosenfeld, M.E., Vickers, S.M., Raben, D., Wang, M., Sampson, L., Feng, M., Jaffee, E. and Curiel, D.T., Pancreatic carcinoma cell killing via adenoviral mediated delivery of herpes simplex virus thymidine kinase gene. Ann. Surg. 1997, 5: 609-620.
99. Rothenberg, M.L., Benedetti, J.K., Macdonald, J.S., Seay T.E., Neubauer, G.C.S., Tanaka, M.S. Jr, Giguere, J.K., Pruitt, B.T. and Abruzzese, J.L., Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann. Oncol. 2002; 13: 1576-1582.
100. Rubanyi, G.M., The future of human gene therapy. Mol Aspects Med. 2001, 22: 113-142.
101. Schmid, R.M., Genetic basis of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2002, 16: 421-433.
102. Schneider, G. and Schmid, R.M., Genetic alterations in pancreatic carcinoma. Mol. Cancer 2003, 2: 15.
103. Schwarte-Waldhoff, I., Volpert, O.V., Bouck, N.P., Sipos, B., Hahn, S.A., Klein-Scory S., Luttges, J., Kloppel, G., Graeven, U., Eilert-Micus, C., Hintelmann, A. and Schmiegel, W., Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. USA 2000, 97: 9624-9629.
104. Shaw, J., Akiyoshi, D.E., Arrigo, D.A., Rhoad, A.E., Sullivan, B., Thomas, J., Genbauffe, F.S., Bacha, P. and Nichols, J.C., Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem. 1991, 266: 21118-21124.
105. Shi, X., Liu, S., Kleeff, J., Friess, H. and Buchler, M.W., Acquired resistance of pancreatic cancer towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62: 354-362.
106. Shirakawa, T., Gardner, T.A., Ko, S.-C., Bander, N., Woo, S., Gotoh, A., Kamidono, S., Chung, L.W.K. and Kao, C., Cytotoxicity of adenoviral-mediated cytosine deaminasei plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J. Urol. 1999, 162: 949-954.
107. Sperti, C., Pasquali, C., Piccoli, A. and Pedrazzoli, S., Recurrence after resection for ductal adenocarcinoma of the pancreas. World J. Surg. 1997, 21: 195-200.
108. Su, Z., Lebedeva, I.V., Gopalkrishnan, R.V., Goldstein, N.I., Stein, C.A., Reed, J.C., Dent, P. and Fisher, P.B., A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc. Natl. Acad. Sci. USA 2001, 98: 10332-10337.
109. Tada, H., Maron, D.J., Choi, E.A., Barsoum, J., Lei, H., Xie, Q., Liu, W., Ellis, L., Moscioni, A.D., Tazelaar, J., Fawell, S., Qin, X., Propert, K.J., Davis, A., Fraker, D.L., Wilson, J.M. and Spitz, F.R., Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases. J. Clin. Invest. 2001, 108: 83-95.
110. Tada, M., Ohashi, M., Shiratori, Y., Okudaira, T., Komatsu, Y., Kawabe, T., Yoshida, H., Machinami, R., Kishi, K. and Omata, M., Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996, 110: 227-231.
111. Tateishi, K., Tada, M., Yamagata, M., Isayama, H., Komatsu, Y., Kawabe, T., Shiratori, Y. and Omata, M., High proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesions. Gut 1999, 45: 737-740.
112. Tseng, J.F. and Mulligan, R.C., Gene therapy for pancreatic cancer. Surg. Oncol. Clin. N. Am. 2002, 11: 537-569.
113. Tsuchida, T., Kijima, H., Hori, S., Oshika, Y., Tokunaga, T., Kawai, K., Yamazaki, H., Ueyama, Y., Scanlon, K.J., Tamaoki, N. and Nakamura, M., Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther. 2000, 7: 373-383.
114. Ugai, S.-I., Shimozato, O., Yu, L., Wang, Y.-Q., Kawamura, K., Yamamoto, H., Yamaguchi, T., Saisho, H., Sakiyama, S. and Tagawa, M., Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and independent antitumor effects. Cancer Gene Ther. 2003, 10: 771-778.
115. Vermes, A., Guchelaar, H.-J. and Dankert, J., Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. JAC 2000, 46: 171-179.
116. Vernejoul, F., Faure, P., Benali, N., Calise, D., Tiraby, G., Pradayrol, L., Susini, C. and Buscail, L., Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 2002, 62: 6124-6131.
117. Wang, J., Xiao-Xuan, L., Dao-Zhen, C., Shu-Feng, L. and Li-Shan, Z., herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J. Gastroenterol. 2004, 10: 400-403.
118. Wang, X.-P., Yazawa, K., Yang, J., Kohn, D., Fisher, W.E. and Brunicardi, C., Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J. Gastrointest. Surg. 2004, 8: 98-108.
119. Weijzen, S., Velders, M.P. and Kast, W.M., Modulation of the immune response and tumor growth by activated Ras. Leukemia 1999, 13: 502-513.
120. Wesseling, J.G., Bosnia, P.J., Krasnykh, V., Kashentseva, E.A., Blackwell, J.L., Reynolds, P.N., Li, H., Parameshwar, M., Vickers, S.M., Jaffee, E.M., Huibregtse, K., Curiel, D.T. and Dmitriev, I., Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther 2001, 8: 969-976.
121. Wilson, B.A. and Collier, R.J., Diphteria toxin and pseudomonas aeruginosa exotoxin A: Active-site, structure and enzymatic mechanism. Curr Top. Microbiol. Immunol. 1992, 175: 27-41.
122. Wunderlich, M. and Berberich, S.J., Mdm2 inhibition of p53 induces E2F1 transactivation via p21. Oncogene 2002, 21: 4414-4421.
123. Xiong, H.Q. and Abbruzzese, J.L., Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Sem. Oncol. 2002, 29: 31-37.
124. Yamada, Y., Post, S.R., Wang, K., Tager, H.S., Bell, G.I. and Seino, S., Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. PNAS 1992, 89: 251-255.
125. Yang, L., Hwang, R., Pandit, L., Gordon, E.M., Anderson, W.F. and Parekh, D., Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. 1996, 224: 405-417.
126. Yiang, L., Chiang, Y., Lenz, H.-J., Danenberg, K.D., Spears, C.P., Gordon, E.M., Anderson, W.F. and Parekh, D., Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther. 1998, 9: 719-728.
127. Yiang, L., Hwang, R., Chiang, Y., Gordon, E.M., Anderson, W.F. and Parekh, D., Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin. Cancer Res. 1998, 4: 731-741.
128. Yoshida, Y., Tasaki, K., Myauchi, M., Narita, M., Takenaga, K., Yamamoto, H., Yamaguchi, T., Saisho, H., Sakiyama, S. and Tagawa, M., Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. Cancer Gene Ther. 2000, 7: 324-331.
129. Zhang, Y.A., Nemunaitis, J., Scanlon, K.J. and Tong, A.W., Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther. 2000, 7: 2041-2050.